Clinical Trial

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

Study acronym: SOLARIS-1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-11-26; most recent amendment 2026-07-03.
Status change: Not Yet Recruiting → Recruiting 2026-01-02
Trial Details
NCT Number NCT07269210
Lead Sponsor Eli Lilly and Company
Conditions Severe Hypertriglyceridemia
Enrollment 60 participants
Start Date 2025-12-08
Primary Completion 2027-03 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-07